The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
